Showing posts sorted by date for query MDMA. Sort by relevance Show all posts
Showing posts sorted by date for query MDMA. Sort by relevance Show all posts

Friday, May 22, 2026

 

With AUKUS Risks and Aging Fleet, Australia Eyes Japanese Subs as Backup

Collins-class submarine HMAS Rankin: Yuri Ramsey/Department of Defence.
Collins-class submarine HMAS Rankin: Yuri Ramsey/Department of Defence.

Published May 21, 2026 3:32 PM by The Strategist

 

[By Richard Gray]

The reduced Collins-class submarine Life-of-Type Extension (LOTE) program, announced on 19 May, will cost more than previously expected and deliver less capability. The government’s decision to cut back the scope of the work also increases the risk to Australia’s possession of a modern, crewed submarine capability in the next decade.

AUKUS remains the best partnership for Australia to acquire the nuclear-propelled submarines necessary for Australia to manage the most dangerous era since World War II. But the now elevated risk of losing adequate conventional submarine capability in the meantime strengthens the case for preparing a Japanese fallback option.

Canberra should approach Tokyo to see how it could buy or lease Japanese submarines should they be required in the 2030s.

The Collins-class LOTE program as originally planned was always highly risky, so cutting back what will be done to the six submarines to keep them going is an understandable and responsible move. Instead of a more extensive LOTE, equipment on the submarines will be repaired and replaced as judged necessary for each boat. Sensors and weapons will be replaced where possible. The focus will be on maintenance and safety rather than enhanced capability. Replacement of the diesel engines and generators will be done only if judged to be critical.

The cost of the reduced LOTE is estimated at around A$11 billion, double what had been estimated for the full LOTE. This is likely not just because the previous costs were probably greatly underestimated but also because old equipment on the submarines will be increasingly expensive to maintain. Critical elements such as the hulls and in some cases the propulsion systems will be approaching or possibly exceeding 40 years of service by the end of the next decade, increasing the risks to safety and likely requiring intensive monitoring and maintenance.

This raises the question of value for money. Even if all goes according to the new plan, Australia will pay around A$1.8 billion per boat to keep roughly its current level of conventional submarine capability, at best. In all capability aspects this does not compare favourably with new, modern conventional submarines. For example, Japan’s Taigei?class submarines cost about A$600 million to A$700 million each. If further reductions to the scope of the LOTE occur – and the announcement yesterday leaves this prospect open, pending further engineering studies – a future government might decide that the running cost of an increasingly fragile and shrinking capability is not worth it and cut its losses. This could mean rapid retirement of older Collins-class vessels and even deciding not to extend the lives of some units, leaving a smaller and rapidly ageing submarine force until the arrival of nuclear boats.

The government plans that at any time three Collinses will be in deep maintenance, which will include life-extension work. Two of the remaining three are to be available for operations. Even assuming this can be achieved in what’s still likely to be a risky and technically challenging program, the life-extended submarines will possibly be less stealthy and probably have less endurance than previously planned. They will progressively fall behind newer regional competitors and probably be less able to undertake the full suite of required missions.

The reduction in planned submarine capability as a result of the de-scoped LOTE program increases the importance of achieving the remaining two key steps of the AUKUS Optimal Pathway, delivery to the Royal Australian Navy of US Virginia-class nuclear attack submarines (SSNs) and local construction of the follow-on Anglo-Australian SSN-AUKUS class.

The Virginias are due to arrive in the early 2030s, almost certainly not before 2032. But there is a significant risk that deliveries could be delayed – or even withheld if the US judges that it has too few SSNs for its own requirements. Since the Collins class is losing its competitiveness with age, delays to the Virginias and SSN-AUKUS could leave Australia without a modern crewed submarine capability for a decade or more – hence the need to get ready now for the Japanese fallback option.

As the ASPI report Hedging our Bets recommends, it is more than prudent to prepare now for the future contingency of rapidly buying or leasing conventional submarines from Japan (or even another partner) should these risks to Australia’s submarine capability emerge. The reduction in the LOTE program and resulting reduction in planned capability is a clear reminder that such risks are very real.

Richard Gray is a resident senior fellow at ASPI.

The opinions expressed herein are the author's and not necessarily those of The Maritime Executive.


Australia ‘disappointed’ by Chinese owner’s resistance to forced port sale



By AFP
May 21, 2026


Private Chinese company Landbridge acquired a 99 year lease to Darwin Port in 2015, prompting criticism of Australia from then-US President Barack Obama 
- Copyright AFP Jung Yeon-je

Australia’s defence minister Richard Marles said Thursday that Canberra was “disappointed” the Chinese leaseholder of the strategic Darwin Port was challenging efforts to return it to local ownership.

Private Chinese company Landbridge acquired a 99 year lease to Darwin Port in 2015, prompting criticism of Australia from then-US president Barack Obama.


Prime Minister Anthony Albanese pledged last year to return the northern port — which sits across the harbour from a defence base hosting 2,000 US Marines annually and tarmacs upgraded for US bomber aircraft — to Australian ownership.

In April, Landbridge’s billionaire owner Ye Cheng lodged a complaint in the World Bank’s tribunal for investment disputes, alleging Australia’s push for the company to sell the port had breached its free trade agreement with China and was taking a discriminatory approach.

“We’re committed to putting the Port of Darwin back into Australian hands,” Marles told reporters Thursday on a visit to Darwin.

“We’re disappointed about the steps that have been taken to put this toward the place of an international tribunal. Obviously, we will do everything in our power to defend that matter,” he said.

Marles also noted the US military was committed to “doing more from Darwin”.

Darwin is Australia’s closest port to Asia, and cargo shipments of commodities including iron ore and liquefied natural gas to China have dominated trade ties.

In January, China’s ambassador to Australia Xiao Qian warned if Landbridge were forced to leave the port it could impact wider trade and investment between China and Australia.


Australian Police Intercept a Diesel Generator Filled With Multiple Drugs

Drug packages within an apparent cylinder bore (AFP)
Drug packages encapsulated within an apparent cylinder liner, post-disassembly (AFP)

Published May 21, 2026 9:32 PM by The Maritime Executive


The Australian Federal Police are calling on diesel repair specialists to help with a rare technical problem: the agency has confiscated a used diesel generator that someone packed full with nearly every kind of illegal stimulant on the market, and it needs to find the people responsible for the shipment.

Early this year, Australian Border Force inspectors at Port Botany were conducting routine X-ray inspections of imported cargoes when they noticed something off about a heavy-duty diesel generator, which had arrived from Mexico by way of Malaysia. 

This generator was special: it appeared to have packages inside. The ABF contacted the AFP, who brought in specialists to have a closer look. Over the course of three days, they disassembled the generator and found a total of about 370 kilos of drugs inside; photos suggest the consignment was stashed in a cylinder bore.

Unusually, the shipment was very diverse. Large-scale imports typically have just one or two drug classes, but this one had about 120 kilos of cocaine, 250 kilos of methamphetamine, three kilos of MDMA and 800 grams of 2CB ("pink cocaine"), a lab-made club drug with stimulant and psychedelic effects.  

"This mixed bag of illicit drugs was likely destined for several different criminal groups, to be sold into a range of communities. Despite the elaborate attempt to conceal such a large quantity of drugs, the coordinated efforts of law enforcement ensured these substances never reached Australian streets," said Detective Acting Superintendent Stuart Kimbell in a statement. 

Kimbell said that the AFP is looking for tips from the public - particularly from anyone who might have been approached about storage space for a generator, or spare parts vendors or diesel engine technicians who may have fielded inquiries about repairs. (The make and model of the engine were not released.)

According to ABF, this intercept ranked high on the list for technical complexity and detection difficulty. "ABF officers are highly skilled at identifying anomalies across all forms of incoming cargo, no matter how elaborate the concealment," said ABF Superintendent Jared Leighton.

Separately, the AFP announced that it had busted the alleged ringleader of an insider smuggling network at Port Botany. The 29-year-old suspect stands accused of organizing multiple drug pickup attempts at the port, including a 500-kilo shipment last year. The organizer allegedly paid a competitive wage to entice co-conspirators, up to US$140,000 per person per pickup - nearly three years of earnings for a typical Australian worker. 

Australia is the world's leading per-capita consumer market for cocaine and methamphetamine, and import prices are accordingly high. While wholesale prices fluctuate with availability, cocaine typically attracts more than US$100,000 per kilo on the Australian market. 

Wednesday, May 20, 2026


‘Profound Disappointment’: Democratic Virginia Gov. Spanberger Vetoes Legal Cannabis Sales

“The governor’s decision leaves the commonwealth exactly where we have been since 2021: with an unchecked illicit market hurting our communities, harming our youth, and putting adults at risk,” said one critic.


Then-Congresswoman Abigail Spanberger (D-Va.) speaks during a press conference in Fredericksburg, Virginia on November 3, 2022.
(Photo by Samuel Corum/Getty Images)


Brett Wilkins
May 19, 2026
COMMON DREAMS

Criminal justice reform and cannabis legalization advocates led condemnation of Democratic Virginia Gov. Abigail Spanberger’s Tuesday veto of legislation that would have established a retail market for the sale of recreational-use marijuana, which has been legal in the state for five years.

In 2021, Virginia became the then-16th state to pass an adult-use marijuana legalization law, with sales set to begin in 2024. However, former Republican Gov. Glenn Youngkin repeatedly vetoed the legislation, which would establish the framework for regulating and taxing the plant’s recreational use.

Today, while adults can legally consume cannabis recreationally, cannabis sales in Virginia are still restricted to medical use, and patients must travel to one of the five licensed providers in the commonwealth.

In March, Virginia lawmakers passed a package of bills to legalize recreational cannabis sales to people age 21 and older via a regulated market, place oversight of such sales under the Virginia Cannabis Control Authority, increase the public possession limit from one ounce to 2.5 ounces, allow delivery sales, establish new state and local cannabis taxes, and set January 1, 2027 as the launch date for sales.

Spanberger—who had campaigned on a promise to sign legislation establishing recreational cannabis sales—proposed amendments to the bill that were rejected by the General Assembly.

“I support the intent of many of the bills I am vetoing,” she explained in a statement. “However, it is my responsibility as governor to make sure all new laws can be successfully implemented and protect against unintended consequences that harm Virginians.”

“I look forward to continuing to work with bill patrons, state and local leaders, and advocates on legislation addressing these issues in the future,” the governor said.

Marijuana Moment reported that Spangberger sought to delay the start of sales by six months, increase taxes, and institute new criminal penalties for cannabis consumers.

“Once again, Virginia’s efforts to establish a safe, regulated, and equitable adult-use cannabis marketplace has been halted despite years of work, public input, and broad recognition that the status quo is failing Virginians,” state Sen. Lashrecse Aird (D-63), who sponsored one of the bills, said in a statement Tuesday.

“The governor’s decision leaves the commonwealth exactly where we have been since 2021: with an unchecked illicit market hurting our communities, harming our youth, and putting adults at risk,” she added.

Del. Paul Krizek (D-16), who sponsored the House of Delegates version of the sales bill, said, “Five years ago, Virginia legalized cannabis in recognition that the War on Drugs has caused disproportionate harm to Black families and communities.”

“The question now is whether Virginia will continue allowing an unregulated illegal market to thrive, or finally establish a safe, transparent system that protects consumers, keeps products away from children, and keeps our commitment to ending racially discriminatory marijuana policing in Virginia,” he added.

JM Pedini, development director for the advocacy group National Organization for the Reform of Marijuana Laws and executive director for Virginia NORML, told Marijuana Moment that Spanberger’s veto is “a profound disappointment to the many Virginia voters who believed her when she said on the campaign trail that she supported establishing a regulated adult-use cannabis market.”

“It is also a slap in the face to the years of serious work undertaken by lawmakers, policy experts, advocates, public health stakeholders, and regulators who spent more than half a decade researching, debating, and carefully crafting this legislation,” Pedini added. “Rather than build upon that work, the governor dismissed it in favor of out-of-touch proposals to recriminalize cannabis consumers that lawmakers rightly rejected.”



Chelsea Higgs Wise, executive director of the Richmond-based nonprofit Marijuana Justice, said in a statement that “for five years, Virginia has been stuck in a limbo where adults can legally possess, share, and grow cannabis, but there is still no regulated way to purchase it.”

“By rejecting the retail bill,” Wise added, “the governor has chosen to extend that chaos rather than move us toward a transparent, accountable retail system that centers public health, public safety, and justice.”

Twenty-four states have legalized recreational marijuana, while 16 states allow medical use of the plant. Last month, the US Department of Justice began reclassifying cannabis from Schedule I—a category that includes dangerous drugs like heroin, LSD, and MDMA to Schedule III, which includes codeine, ketamine, anabolic steroids, and testosterone.

Sunday, May 17, 2026

 

Trip to recovery: How psychedelics could revolutionise mental health care

Psychedelic-assisted therapies have shown promise in treating the cognitive ruts of several mental health conditions.
Copyright Canva

By Amber Louise Bryce
Published on


In a world gripped by a growing mental health crisis, research suggests that psychedelic-assisted therapy could be an answer. Euronews Health spoke to an expert about how they work, and when - if ever - we might see them approved.

Picture this: You walk into a small, dimly lit room and lay on a bed beside a clinician. After talking you through what’s going to happen, they hand you an eye mask, then administer a controlled dose of the psychedelic compound, psilocybin.

As suddenly as the drug takes effect, the world as you knew it starts to dissolve - the chains of old thought patterns finally loosen.

While it might sound intense, this scenario could be a future reality for those living with treatment resistant mental illness, including depression and post traumatic stress disorder (PTSD).

In recent years, psychedelic-assisted therapies have become one of the most fascinating and fast-accelerating areas of psychiatric research, driven by an ever-growing body of exciting new evidence.

The current mental health crisis has also created an urgency for new, more effective treatment options, with over a billion people currently living with mental health disorders, according to the World Health Organization (WHO).

“Unfortunately, in mental health, and specifically in psychiatry, we haven't really had any new treatments for several decades,” Dr Liliana Galindo, an assistant professor at the University of Cambridge’s psychiatry department, told Euronews Health.

“What psychedelics are bringing is the opportunity to have or to present new treatments for people that don't respond to the usual treatments.”

Psychedelics are a class of psychoactive substances that can powerfully alter people's perceptions and moods by binding to serotonin receptors. Popular examples include psilocybin, DMT, phenethylamines (MDMA) and lysergamides (LSD).

While they all share similar consciousness-expanding qualities, each compound varies in its intensity, duration, and overall effect, with different ones being tested for different conditions.

So far, psilocybin, an active ingredient in magic mushrooms, has generated the most promising results.

“For treating depression, psilocybin, specifically the COMP360 (a synthetic formulation of psilocybin developed by Compass Pathways), has already finished phase three of its clinical trials. We are expecting that [Compass] is going to file the FDA (Food and Drug Administration) application soon,” Galindo said.

“Potentially, this could be the very first psychedelic treatment that will be legal and approved.”

How do psychedelic-assisted therapies work?

Up until now, mental health treatments have relied on two evidence-based methods: talk therapies and medications such as antidepressants.

These are proven to be effective, with patients receiving a combination of the two 25-27% more likely to respond positively, according to statistics by the National Institutes of Health.

But for those that don’t respond, other avenues of help remain limited.

“Many mental health conditions have some symptoms that are common, like rigid cognitions. So, for example, when people are depressed, they start to have really negative thoughts, and these negative thoughts are going to affect how they see themselves, how they see the world, and of course, how they are going to feel about it. And after several years of being depressed, it's really difficult to take a step outside of those pessimistic thoughts, or frequent fears and even suicidal ideations,” Galindo explained.

For these cases, psychedelic medications could be the answer, with Galindo noting their effectiveness at disrupting cognitive ruts and rewiring how the brain processes trauma.

“I really like an analogy I saw once [about psychedelic medications] that it's like when you're skiing. You usually go for a certain pathway, right? And because the pathway has a specific mark, it is really difficult to actually go outside of it. But somehow, what psilocybin allows, is like having fresh snow that will make it easier to actually explore different pathways.”

Numerous studies back this, with a recent one by Imperial College London - considered a world leader in psychedelic research - reporting that even a single dose of psilocybin can prompt anatomical changes in the brain.

Other psychoactive compounds such as MDMA have been shown to work a little differently by enhancing feelings of empathy, connectivity and openness, which could be effective at treating PTSD.

“It facilitates a period of time where people [with PTSD] can revisit their memories and somehow be able to rethink, to reframe, to change the narrative and to process their trauma,” she said.

“This is the reason psychedelics are bringing such a big revolution to mental health, because they're aiming to treat the core rather than only the symptoms.”

Social stigmas and legal issues

A major hurdle to mainstream approval, however, remains their status as illegal drugs in most countries.

“Unfortunately, even if we have clear evidence for their therapeutic potential, they are still illegal. For example, here in the UK, they're still classified A, meaning that in order to conduct any study, we need to apply for a special home office licence. This is not only expensive, but takes a long time, and so is definitely affecting the amount of research that could be happening in the field,” Galindo said.

Another issue is the stigmas surrounding these drugs, and their primary associations with party culture and potentially dangerous outcomes.

Galindo emphasises that these concerns are why the controlled setting of psychedelic-assisted therapies is so important.

“You need to take care of all the different details of the environment, like the sound, the lights. And of course, the entire time [the patient] is supported by a trained therapist or a member of the staff that is there to be able to support during that process,” she said.

“These drugs are really powerful tools, but of course, if for any reason they are not given in the right setting, this could come with more side effects.”

While more research is required to better understand who will benefit and who won’t, Galindo hopes that, one day, these treatments can become an accessible option for everyone.

“Rather than staying in a private setting, they should be available for the people who need it the most, not only for the ones that can pay.”

Tuesday, May 05, 2026

 

Cannabis microdosing more common than psychedelics among US adults, national survey finds



Across substances, people reporting poorer mental health were more likely to report microdosing




University of California - San Diego






Key takeaways:

  • Cannabis is the most commonly microdosed substance in the U.S., with about 9.4% of adults — roughly 24 million people — reporting lifetime use. More people reported microdosing for recreational reasons than for medical reasons.

  • Cannabis microdosing was nearly twice as common as psilocybin, LSD or MDMA, challenging the perception that microdosing is mainly a psychedelic practice.

  • Microdosing was more common among people reporting poorer mental health.

Researchers from University of California San Diego have found that microdosing — taking very small amounts of psychoactive substances — is more common among U.S. adults than previously recognized, with cannabis leading by a wide margin. The study, published May 4, 2026 in the American Journal of Preventive Medicine, estimates that millions of Americans have microdosed substances such as cannabis, psilocybin, LSD (“acid”) and MDMA (“ecstasy”).

“Microdosing is often discussed in the context of psychedelics like psilocybin or LSD, but what surprised us most was that cannabis microdosing was almost twice as common,” said Kevin Yang, MD, resident physician in the Department of Psychiatry at UC San Diego School of Medicine and first author of the study. “That suggests conversations about microdosing may be overlooking a large group of people who are using small amounts of cannabis in similar ways.”

“Most proponents of microdosing recommend use under specific protocols that involve taking low doses of LSD or psilocybin for specific health applications,” said Eric Leas, PhD, MPH, assistant professor at the UC San Diego Herbert Wertheim School of Public Health and Human Longevity Science and senior author of the study. “That’s not what we found. Most people are microdosing for recreational purposes. That suggests that many people could think about the concept of ‘microdosing’ more as a way of lowering dosage. They may just want to take less, so they don’t want to get as high.”

Microdosing typically involves consuming about one-fifth to one-twentieth of a typical recreational dose, with the goal of avoiding strong psychoactive effects while potentially experiencing subtler benefits such as improved mood, reduced anxiety or enhanced creativity.

To better understand how common the practice is, researchers analyzed data from a nationally representative survey of 1,525 U.S. adults conducted in late 2023 through the Ipsos KnowledgePanel, which uses probability-based sampling to reflect the U.S. population. Participants were asked whether they had ever intentionally microdosed cannabis, psilocybin mushrooms, LSD or MDMA.

The results suggest that cannabis is the most commonly microdosed substance. About 9.4% of U.S. adults — an estimated 24.1 million people — reported microdosing cannabis at least once in their lifetime. In comparison, 5.3% reported microdosing psilocybin, 4.8% LSD and 2.2% MDMA.

Ongoing microdosing was less common but still measurable: roughly 3.3% of adults reported currently microdosing cannabis, compared with about 1.0% for psilocybin, 0.6% for LSD and 0.3% for MDMA.

The study also found that the reasons for microdosing differed by substance. Cannabis microdosing was most often reported for medical reasons, including managing anxiety, depression or chronic pain. In contrast, psilocybin, LSD and MDMA were more frequently microdosed for recreational purposes, such as achieving a milder psychoactive experience.

Researchers also observed patterns tied to mental health and policy environments. Across substances, people reporting poorer mental health were more likely to report microdosing. For example, cannabis microdosing was reported by about 21% of adults who rated their mental health as “poor,” compared with about 8% among those reporting “excellent” mental health.

In addition, microdosing of psychedelics such as psilocybin and LSD was more common in places where laws were more permissive — meaning, jurisdictions that have decriminalized psychedelic possession. The findings suggest that changes in drug policy may influence both access to these substances and people’s willingness to report using them.

Despite growing public interest, the researchers emphasize that scientific evidence on the health effects of microdosing remains limited. Few placebo-controlled clinical trials have been conducted and existing studies have produced mixed findings about potential benefits. Additional risks stem from the unregulated nature of many of these substances, including the possibility of adulterated products or dosing errors — especially since most people who microdose do not test the substances they use.

“There’s a lot of anecdotal enthusiasm around microdosing, especially for mental health,” said Leas. “But we still need rigorous studies to determine whether these perceived benefits are real, who might benefit and what the potential risks could be.”

The authors note that because the study was cross-sectional, it cannot determine whether microdosing influences mental health outcomes or whether people experiencing mental health challenges are more likely to try microdosing. Future research, including longitudinal studies and clinical trials, will be needed to clarify those relationships.

As cannabis legalization and psychedelic policy reforms continue to evolve across the United States, the researchers say monitoring patterns of microdosing will become increasingly important for public health.

“Microdosing appears to be a growing behavior that cuts across different substances and motivations,” Leas said. “Understanding how and why people are using these small doses is essential if we want to develop evidence-based policies and guidance for clinicians and the public.”

Link to full study: https://doi.org/10.1016/j.amepre.2026.108381

Additional co-authors on the study include: Joseph Friedman, MD, and Siyuan Ping from UC San Diego. Nora Satybaldiyeva, PhD, and Wayne Kepner, PhD, from Stanford University.

The study was funded, in part, by the U.S. National Institute on Drug Abuse (grant #K01DA054303, PI: Leas). Satybaldiyeva acknowledges salary support from the National Heart, Lung, and Blood Institute (grant #5T32HL161270-03). Kepner acknowledges salary support from the National Institute on Drug Abuse of the National Institutes of Health (#T32DA035165), and the William and Katharine Duhamel Addiction Medicine Fund.

Authors declare no competing interests.

Sunday, March 08, 2026

 

Less trippy, more therapeutic ‘magic mushrooms’




American Chemical Society




Psilocybin — the psychoactive compound in “magic mushrooms” — is gaining scientific attention for its potential in treating neuropsychiatric conditions including depression, anxiety, substance use disorders and certain neurodegenerative diseases. However, its hallucinogenic effects may limit broader therapeutic applications. Researchers publishing in ACS’ Journal of Medicinal Chemistry synthesized modified versions of psilocin, the active form of psilocybin, that retained their activity while producing fewer hallucinogenic-like effects than pharmaceutical-grade psilocybin in a preliminary study in mice. 

“Our findings are consistent with a growing scientific perspective suggesting that psychedelic effects and serotonergic activity may be dissociated,” says Andrea Mattarei, a corresponding author of the study. “This opens the possibility of designing new therapeutics that retain beneficial biological activity while reducing hallucinogenic responses, potentially enabling safer and more practical treatment strategies.”  

Mood disorders and some neurodegenerative diseases, such as Alzheimer’s disease, involve imbalances of the neurotransmitter molecule serotonin, which helps regulate mood and other brain functions. For decades, scientists have been investigating the therapeutic use of psychedelics such as psilocybin on serotonin-signaling pathways. However, the hallucinations that can accompany these drugs may make people wary of taking them, even if there is a medical benefit. 

So, a team led by Sara De Martin, Mattarei and Paolo Manfredi chemically engineered five psilocin derivatives for slower, sustained and potentially non-hallucinogenic release into the brain. They first tested these five compounds using human plasma samples and laboratory conditions mimicking gastrointestinal absorption. These experiments allowed the team to identify a compound they named 4e as the most promising candidate because it displayed favorable stability for absorption and enabled a gradual release of psilocin — a feature that could potentially mitigate hallucinogenic effects. Importantly, 4e retained activity at key serotonin receptors at levels comparable to psilocin. 

Next, the researchers compared the effects of equivalent doses of 4e with pharmaceutical-grade psilocybin in mice. The team administered the compounds orally to mice and measured how much psilocin reached the bloodstream and brain over a 48-hour period. In mice dosed with 4e, the compound was able to cross the blood–brain barrier effectively and exhibited a lower but more sustained presence of psilocin in their brains compared to those treated with psilocybin. When the researchers looked at mouse behavior, they observed that 4e-treated animals exhibited significantly fewer head twitches — a well-established marker of psychedelic-like activity in rodents — than those receiving psilocybin, despite the strong serotonin receptor activity of 4e. This behavioral difference appeared to be associated primarily with the amount and timing of psilocin released in the brain.  

The researchers say their findings demonstrate the feasibility of developing stable brain-penetrating psilocin derivatives that retain serotonin receptor activity while reducing acute mind-altering effects. Further studies will be needed to clarify their mechanism of action and fully characterize their biological effects before assessing their therapeutic potential and safety in humans.  

The authors acknowledge funding from MGGM Therapeutics, LLC, in collaboration with NeuroArbor Therapeutics Inc. Several authors declare they are inventors on patents related to psilocin.  

### 

The American Chemical Society (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio. 

Registered journalists can subscribe to the ACS journalist news portal on EurekAlert! to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org

Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies. 

Follow us: Facebook | LinkedIn | Instagram